Credit Suisse analyst Martin Auster maintained a Buy rating on Alexion Pharmaceuticals (ALXN) on September 5 and set a price target of $146. The company’s shares closed last Monday at $106.40.
According to TipRanks.com, Auster is a 1-star analyst with an average return of -0.7% and a 42.4% success rate. Auster covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Stoke Therapeutics Inc.
Alexion Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $164.89, implying a 58.6% upside from current levels. In a report issued on August 21, Morgan Stanley also reiterated a Buy rating on the stock with a $177 price target.
See today’s analyst top recommended stocks >>
Alexion Pharmaceuticals’ market cap is currently $23.86B and has a P/E ratio of 17.98. The company has a Price to Book ratio of 2.35.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P.
